Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) Interest Expenses (2016 - 2023)

Dexcom (DXCM) has disclosed Interest Expenses for 14 consecutive years, with $5.9 million as the latest value for Q2 2023.

  • On a quarterly basis, Interest Expenses rose 25.53% to $5.9 million in Q2 2023 year-over-year; TTM through Mar 2024 was $5.9 million, a 68.28% decrease, with the full-year FY2022 number at $18.6 million, down 1.06% from a year prior.
  • Interest Expenses was $5.9 million for Q2 2023 at Dexcom, up from $4.6 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $25.2 million in Q2 2021 to a low of -$42.4 million in Q4 2020.
  • A 5-year average of $9.3 million and a median of $10.4 million in 2019 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: surged 212.5% in 2019, then tumbled 377.12% in 2020.
  • Dexcom's Interest Expenses stood at $15.3 million in 2019, then crashed by 377.12% to -$42.4 million in 2020, then skyrocketed by 111.08% to $4.7 million in 2021, then changed by 0.0% to $4.7 million in 2022, then rose by 25.53% to $5.9 million in 2023.
  • Per Business Quant, the three most recent readings for DXCM's Interest Expenses are $5.9 million (Q2 2023), $4.6 million (Q1 2023), and $4.7 million (Q4 2022).